A Phase 3 interventional study of Rotarix and Pediarix in Rotavirus Infection and Rotavirus Vaccines, sponsored by GlaxoSmithKline. Completed at 47 sites in United States. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-29.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Rotavirus Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Rotavirus Infections · GlaxoSmithKline.
Among the 61 studies in Rotavirus Infections by GlaxoSmithKline, this one is the 12th largest by enrollment of the 38 interventional ones that give a count, is the only one that started in 2017, is one of 23 in phase 3, and was the 60th registered.
104 studies on the registry are indexed under Rotavirus Infections; 3 are open to participants now.
Browse Rotavirus Infections studies →None of the 61 studies in Rotavirus Infections by GlaxoSmithKline is open now. The open studies under Rotavirus Infections, anywhere →
Of the 3 Rotavirus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 6 Weeks to 12 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,280 is above the median of 403 across 69 interventional studies indexed under Rotavirus Infections.
Median enrollment 507 across the 38 interventional studies, 522 across the 23 observational. Of the 59 that completed or were terminated, 21 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 61 studies in Rotavirus Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess if there is any immune interference between the Porcine circovirus free (PCV-free) liquid Human rotavirus (HRV) vaccine and routine infant vaccinations currently in use in the US, namely Pediarix®, Hiberix® and Prevenar 13® as compared to the currently licensed lyophilized formulation of the HRV vaccine when co-administered with the same routine vaccinations in healthy infants 6-12 weeks of age
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Acute disease and/or fever at the time of enrolment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy female or male subjects, between and including 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in PCV-free liquid formulation, according to a 0, 2-month schedule, co-administered with one dose of each Pediarix, Hiberix and Prevnar-13 at three timepoints (day 1, month 2 and month 4). PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
Biological: Rotarix · Biological: Pediarix · Biological: Hiberix · Biological: Prevenar 13
Healthy female or male subjects, between and including 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in lyophilized formulation, according to a 0, 2-month schedule, co-administered with one dose of each Pediarix, Hiberix and Prevnar-13 at three timepoints (day 1, month 2 and month 4).
Biological: Rotarix · Biological: Pediarix · Biological: Hiberix · Biological: Prevenar 13
Two doses administered orally according to a 0, 2 month schedule as per the immunization schedule for HRV vaccine administration in the US.
Also known as: GSK Biologicals' PCV-free liquid formulation of oral live attenuated HRV vaccine., GSK Biologicals' lyophilized formulation of oral live attenuated HRV vaccine.
Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
Also known as: GSK Biologicals' Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine.
Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
Also known as: GSK Biologicals' Haemophilus b conjugate vaccine (tetanus toxoid conjugate)
Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
Also known as: Pfizer's Pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 Protein)
Number of Seroprotected Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Above or Equal to Cut-off Value.
Immunogenicity was assessed using Enzyme Linked Immunosorbent Assay (ELISA) in terms of seroprotection rates against diphtheria toxoid. A seroprotected subject is a subject whose antibody concentration is greater than or equal to (≥) the level defining clinical protection. The following seroprotection thresholds were applicable:anti-D antibody concentrations ≥ 0.1 International Units/milliliter (IU/mL), anti-T antibody concentrations ≥ 0.1 IU/mL.
Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)
Number of Seroprotected Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentrations Above or Equal to Cut-off Value.
Immunogenicity was assessed using ChemiLuminescence ImmunoAssay (CLIA) in terms of seroprotection rates against Hepatitis B. A seroprotected subject is a subject whose antibody concentration is ≥ the level defining clinical protection. The following seroprotection thresholds were applicable:anti-HB antibody concentrations ≥ 10 milli International Units/milliliter (mIU/mL).
Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)
Number of Seroprotected Subjects With Anti-polio Virus Types 1, 2 and 3 Antibody Titers Above or Equal to Cut-off Value.
Immunogenicity was assessed using virus micro-neutralization test in terms of seroprotection rates against polio virus types 1, 2 and 3. A seroprotected subject is a subject whose antibody concentration is ≥ the level defining clinical protection. The following seroprotection thresholds were applicable:anti-polio virus types 1, 2 and 3 types antibody titers ≥ 8 Estimated Dose 50% (ED50).
Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)
Immunogenicity in Terms of Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations.
Antibody concentrations against PT, FHA and PRN were determined and expressed as Geometric Mean Concentrations (GMCs).The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.
Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)
Immunogenicity in Terms of Anti-pneumococcal Serotypes (Anti-PnPS) Antibody Concentrations.
Antibody concentrations against pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) were determined and expressed as GMCs in micrograms per milliliter (µg/mL).The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.
Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)
Number of Seroprotected Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Above or Equal to Cut-off Value of 0.15 µg/mL.
Immunogenicity was assessed in terms of seroprotection rates against PRP antibodies. A seroprotected subject is a subject whose antibody concentration is ≥ the level defining clinical protection. The following seroprotection thresholds were applicable:anti-PRP antibody concentrations ≥ 0.15 µg/mL.
Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)
Number of Seroprotected Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Above or Equal to Cut-off Value of 1.0 µg/mL.
Immunogenicity was assessed in terms of seroprotection rates against PRP antibodies. A seroprotected subject is a subject whose antibody concentration is ≥ the level defining clinical protection. The following seroprotection thresholds were applicable:anti-PRP antibody concentrations ≥ 1.0 µg/mL.
Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)
Number of Subjects With Seroresponse to Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies.
Seroresponse is defined as the percentage of subjects showing an antibody concentration above a threshold that leads to 95% seroresponse in the HRV lyophilized Group. The cut-offs used were as follows: anti-PT (18.566 IU/mL), anti-FHA (35.711 IU/mL) and anti-PRN (11.034 IU/mL).
Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)
Number of Seropositive Subjects With Anti-Rota Virus Immunoglobulin A (Anti-RV IgA) Antibody Concentrations Above or Equal to Cut-off Value of 20 Units/Milliliter (U/mL).
Immunogenicity was assessed in terms of seropositivity against Rota virus IgA antibodies. The cut off used was ≥ 20 U/mL.
Time frame: At Month 5 (Three months after Dose 2 of HRV vaccine)
Number of Seropositive Subjects With Anti-RV IgA Antibody Concentrations Above or Equal to Cut-off Value of 90 U/mL.
Immunogenicity was assessed in terms of seropositivity against Rota virus IgA antibodies. The cut off used was ≥ 90 U/mL.
Time frame: At Month 5 (Three months after Dose 2 of HRV vaccine)
Number of Seropositive Subjects With Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations Above or Equal to Cut-off Value.
Immunogenicity was assessed using ELISA technique in terms of seropositivity against PT, FHA and PRN antibodies. The cut-offs for antibodies were the Lower Limit Of Quantification (LLOQ) of the assays which were ≥ 2.693 IU/mL (anti-PT), ≥ 2.046 IU/mL (anti-FHA) and ≥ 2.187 IU/mL (anti-PRN). The Limit of Quantification is the lowest analyte concentration that can be quantitatively detected with a stated accuracy and precision, and LLOQ is the lowest standard curve point obtained by extrapolation, that can still be used for quantification.
Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)
Number of Seropositive Subjects With Anti-PnPS Antibody Concentrations Above or Equal to Cut-off Value.
Immunogenicity was assessed using ELISA technique in terms of seropositivity against Pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) antibodies. The cut-off used was ≥ 0.35 µg/mL.
Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)
Immunogenicity in Terms of Anti-D and Anti-T Antibody Concentrations.
Antibody concentrations against diphtheria and tetanus were determined and expressed as GMCs. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.
Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)
Immunogenicity in Terms of Anti-PRP Antibody Concentrations.
Antibody concentrations against PRP were determined and expressed as GMCs. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.
Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)
Immunogenicity in Terms of Anti-HBs Antibody Concentrations.
Antibody concentrations against Hepatitis B were determined and expressed as GMCs. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.
Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)
Immunogenicity in Terms of Anti-poliovirus Types 1, 2 and 3 Antibody Titers.
Antibody concentrations against Poliovirus types 1, 2 and 3 were determined and expressed as Geometric Mean Titers (GMTs).
Time frame: At Month 5 (One month after Dose 3 of co-administered vaccines)
Number of Subjects With Any Solicited General Adverse Events (AEs).
Assessed solicited general AEs were cough/runny nose; diarrhoea; fever measured by 3 routes which were oral, axillary and rectal, defined as temperature ≥ 38.0 degrees Celsius (°C); irritability; loss of appetite and vomiting. Any = any solicited general AE irrespective of its intensity grade and relationship to vaccination
Time frame: During the 8-day (Days 1-8) follow-up period after each HRV vaccination.
Number of Subjects With Any Unsolicited AEs.
Unsolicited AEs assessed include any AE reported in addition to those solicited during the clinical study. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any= Any unsolicited AE irrespective of its intensity grade and relationship to vaccination.
Time frame: During the 31-day (Days 1-31) follow-up period after each HRV vaccination.
Number of Subjects With Any Serious Adverse Events (SAEs).
SAEs assessed include any untoward medical occurrence that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization or resulted in disability/incapacity.
Time frame: During the entire study period (Day 1 to Month 10)
The study was conducted at 48 centers in the United States (US).
| Milestone | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Started | 632 | 640 |
| Completed | 574 | 574 |
| Not completed | 58 | 66 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Lost to follow-up | 21 | 29 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Consent withdrawal, not due to an ae | 11 | 13 |
| Withdrew: Migrated / moved from the study area | 7 | 10 |
| Withdrew: Not willing to participate this visit | 10 | 5 |
| Withdrew: Not willing / not able to be contacted | 1 | 2 |
| Withdrew: Other, not specified | 5 | 4 |
Immunogenicity was assessed using Enzyme Linked Immunosorbent Assay (ELISA) in terms of seroprotection rates against diphtheria toxoid. A seroprotected subject is a subject whose antibody concentration is greater than or equal to (≥) the level defining clinical protection. The following seroprotection thresholds were applicable:anti-D antibody concentrations ≥ 0.1 International Units/milliliter (IU/mL), anti-T antibody concentrations ≥ 0.1 IU/mL.
| Participants | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Anti-D | 478 | 486 |
| Anti-T | 486 | 495 |
Immunogenicity was assessed using ChemiLuminescence ImmunoAssay (CLIA) in terms of seroprotection rates against Hepatitis B. A seroprotected subject is a subject whose antibody concentration is ≥ the level defining clinical protection. The following seroprotection thresholds were applicable:anti-HB antibody concentrations ≥ 10 milli International Units/milliliter (mIU/mL).
| Participants | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Number of Seroprotected Subjects With Anti-hepatitis B (Anti-HBs) Antibody Concentrations Above or Equal to Cut-off Value. | 457 | 471 |
Immunogenicity was assessed using virus micro-neutralization test in terms of seroprotection rates against polio virus types 1, 2 and 3. A seroprotected subject is a subject whose antibody concentration is ≥ the level defining clinical protection. The following seroprotection thresholds were applicable:anti-polio virus types 1, 2 and 3 types antibody titers ≥ 8 Estimated Dose 50% (ED50).
| Participants | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Anti-Polio 1 | 477 | 486 |
| Anti-Polio 2 | 463 | 478 |
| Anti-Polio 3 | 439 | 454 |
Antibody concentrations against PT, FHA and PRN were determined and expressed as Geometric Mean Concentrations (GMCs).The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.
| IU/mL | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Anti-PT | 51 (47.8 to 54.5) | 54.2 (51.3 to 57.4) |
| Anti-FHA | 107.3 (101.4 to 113.5) | 107.7 (101.6 to 114.1) |
| Anti-PRN | 55 (50.1 to 60.4) | 56.6 (51.9 to 61.7) |
Antibody concentrations against pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) were determined and expressed as GMCs in micrograms per milliliter (µg/mL).The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.
| µg/mL | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Anti-PnPS 1 | 1.95 (1.81 to 2.10) | 1.89 (1.76 to 2.03) |
| Anti-PnPS 3 | 0.53 (0.49 to 0.57) | 0.53 (0.49 to 0.57) |
| Anti-PnPS 4 | 1.24 (1.16 to 1.34) | 1.25 (1.18 to 1.34) |
| Anti-PnPS 5 | 1.28 (1.17 to 1.39) | 1.22 (1.13 to 1.31) |
| Anti-PnPS 6A | 2.84 (2.64 to 3.05) | 2.8 (2.61 to 3.00) |
| Anti-PnPS 6B | 1.93 (1.72 to 2.15) | 2 (1.80 to 2.22) |
| Anti-PnPS 7F | 3.01 (2.83 to 3.21) | 3.04 (2.86 to 3.22) |
| Anti-PnPS 9V | 1.68 (1.56 to 1.81) | 1.63 (1.52 to 1.75) |
| Anti-PnPS 14 | 6.27 (5.74 to 6.84) | 6.26 (5.75 to 6.82) |
| Anti-PnPS 18C | 1.81 (1.68 to 1.95) | 1.76 (1.64 to 1.89) |
| Anti-PnPS 19A | 1.87 (1.73 to 2.02) | 1.8 (1.68 to 1.93) |
| Anti-PnPS 19F | 2.94 (2.76 to 3.12) | 2.85 (2.69 to 3.03) |
| Anti-PnPS 23F | 1.14 (1.04 to 1.24) | 1.16 (1.07 to 1.26) |
Immunogenicity was assessed in terms of seroprotection rates against PRP antibodies. A seroprotected subject is a subject whose antibody concentration is ≥ the level defining clinical protection. The following seroprotection thresholds were applicable:anti-PRP antibody concentrations ≥ 0.15 µg/mL.
| Participants | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Number of Seroprotected Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Above or Equal to Cut-off Value of 0.15 µg/mL. | 473 | 479 |
Immunogenicity was assessed in terms of seroprotection rates against PRP antibodies. A seroprotected subject is a subject whose antibody concentration is ≥ the level defining clinical protection. The following seroprotection thresholds were applicable:anti-PRP antibody concentrations ≥ 1.0 µg/mL.
| Participants | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Number of Seroprotected Subjects With Anti-polyribosyl Ribitol Phosphate (Anti-PRP) Antibody Concentrations Above or Equal to Cut-off Value of 1.0 µg/mL. | 394 | 404 |
Seroresponse is defined as the percentage of subjects showing an antibody concentration above a threshold that leads to 95% seroresponse in the HRV lyophilized Group. The cut-offs used were as follows: anti-PT (18.566 IU/mL), anti-FHA (35.711 IU/mL) and anti-PRN (11.034 IU/mL).
| Participants | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Anti-PT | 440 | 470 |
| Anti-FHA | 466 | 470 |
| Anti-PRN | 455 | 470 |
Immunogenicity was assessed in terms of seropositivity against Rota virus IgA antibodies. The cut off used was ≥ 20 U/mL.
| Participants | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Number of Seropositive Subjects With Anti-Rota Virus Immunoglobulin A (Anti-RV IgA) Antibody Concentrations Above or Equal to Cut-off Value of 20 Units/Milliliter (U/mL). | 318 | 336 |
Immunogenicity was assessed in terms of seropositivity against Rota virus IgA antibodies. The cut off used was ≥ 90 U/mL.
| Participants | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Number of Seropositive Subjects With Anti-RV IgA Antibody Concentrations Above or Equal to Cut-off Value of 90 U/mL. | 219 | 238 |
Immunogenicity was assessed using ELISA technique in terms of seropositivity against PT, FHA and PRN antibodies. The cut-offs for antibodies were the Lower Limit Of Quantification (LLOQ) of the assays which were ≥ 2.693 IU/mL (anti-PT), ≥ 2.046 IU/mL (anti-FHA) and ≥ 2.187 IU/mL (anti-PRN). The Limit of Quantification is the lowest analyte concentration that can be quantitatively detected with a stated accuracy and precision, and LLOQ is the lowest standard curve point obtained by extrapolation, that can still be used for quantification.
| Participants | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Anti-PT | 485 | 495 |
| Anti-FHA | 486 | 495 |
| Anti-PRN | 486 | 495 |
Immunogenicity was assessed using ELISA technique in terms of seropositivity against Pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) antibodies. The cut-off used was ≥ 0.35 µg/mL.
| Participants | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Anti-PnPS 1 | 442 | 463 |
| Anti-PnPS 3 | 317 | 322 |
| Anti-PnPS 4 | 434 | 453 |
| Anti-PnPS 5 | 409 | 424 |
| Anti-PnPS 6A | 441 | 461 |
| Anti-PnPS 6B | 407 | 434 |
| Anti-PnPS 7F | 448 | 466 |
| Anti-PnPS 9V | 431 | 454 |
| Anti-PnPS 14 | 441 | 454 |
| Anti-PnPS 18C | 436 | 451 |
| Anti-PnPS 19A | 438 | 458 |
| Anti-PnPS 19F | 448 | 465 |
| Anti-PnPS 23F | 409 | 425 |
Antibody concentrations against diphtheria and tetanus were determined and expressed as GMCs. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.
| IU/mL | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Anti-D | 1.85 (1.72 to 1.98) | 1.88 (1.75 to 2.02) |
| Anti-T | 1.88 (1.75 to 2.02) | 1.86 (1.74 to 1.99) |
Antibody concentrations against PRP were determined and expressed as GMCs. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.
| µg/mL | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Immunogenicity in Terms of Anti-PRP Antibody Concentrations. | 4.41 (3.82 to 5.09) | 4.28 (3.71 to 4.94) |
Antibody concentrations against Hepatitis B were determined and expressed as GMCs. The GMC calculations were performed by taking the anti-log of the mean of the log concentration transformations.
| mIU/mL | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Immunogenicity in Terms of Anti-HBs Antibody Concentrations. | 2031.3 (1834.6 to 2249.0) | 2168.9 (1977.5 to 2378.9) |
Antibody concentrations against Poliovirus types 1, 2 and 3 were determined and expressed as Geometric Mean Titers (GMTs).
| Titers | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Anti-Polio 1 | 747.2 (673.5 to 828.8) | 728.2 (656.3 to 808.0) |
| Anti-Polio 2 | 659.6 (587.9 to 740.0) | 699.3 (627.7 to 779.0) |
| Anti-Polio 3 | 1228.7 (1100.3 to 1372.1) | 1291.6 (1159.1 to 1439.3) |
Assessed solicited general AEs were cough/runny nose; diarrhoea; fever measured by 3 routes which were oral, axillary and rectal, defined as temperature ≥ 38.0 degrees Celsius (°C); irritability; loss of appetite and vomiting. Any = any solicited general AE irrespective of its intensity grade and relationship to vaccination
| Participants | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Cough / Runny Nose (Dose 1), Any | 172 | 180 |
| Cough / Runny Nose (Dose 2), Any | 224 | 222 |
| Cough / Runny Nose (Across doses), Any | 305 | 313 |
| Diarrhea (Dose 1), Any | 39 | 36 |
| Diarrhea (Dose 2), Any | 34 | 26 |
| Diarrhea (Across doses), Any | 69 | 55 |
| Fever (Dose 1), ≥ 38.0°C | 36 | 32 |
| Fever (Dose 2), ≥ 38.0°C | 64 | 75 |
| Fever (Across doses), ≥ 38.0°C | 89 | 95 |
| Irritability / Fussiness (Dose 1), Any | 448 | 458 |
| Irritability / Fussiness (Dose 2), Any | 440 | 427 |
| Irritability / Fussiness (Across doses), Any | 523 | 522 |
| Loss of appetite (Dose 1), Any | 204 | 214 |
| Loss of appetite (Dose 2), Any | 179 | 178 |
| Loss of appetite (Across doses), Any | 292 | 293 |
| Vomiting (Dose 1), Any | 110 | 105 |
| Vomiting (Dose 2), Any | 83 | 78 |
| Vomiting (Across doses), Any | 147 | 148 |
Unsolicited AEs assessed include any AE reported in addition to those solicited during the clinical study. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any= Any unsolicited AE irrespective of its intensity grade and relationship to vaccination.
| Participants | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Number of Subjects With Any Unsolicited AEs. | 294 | 327 |
SAEs assessed include any untoward medical occurrence that resulted in death, were life-threatening, required hospitalization or prolongation of existing hospitalization or resulted in disability/incapacity.
| Participants | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| Number of Subjects With Any Serious Adverse Events (SAEs). | 20 | 19 |
Collected over Solicited AEs: During the 8-day (Day 1 to Day 8) follow-up period after each HRV vaccination. Unsolicited AEs: During the 31-day (Day 1 to Day 31) follow-up period after each HRV vaccination. SAEs: Throughout the study period (Day 1 to Month 10).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HRV Porcine Circovirus (PCV)-Free Liquid Group | 1/632 (0.2%) | 20/632 (3.2%) | 571/632 (90.3%) |
| HRV Lyophilized Group | 0/640 (0%) | 19/640 (3%) | 589/640 (92%) |
| Event | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| BronchiolitisInfections and infestations | 5/632 | 4/640 |
| Respiratory syncytial virus bronchiolitisInfections and infestations | 3/632 | 4/640 |
| DehydrationMetabolism and nutrition disorders | 2/632 | 1/640 |
| PneumoniaInfections and infestations | 2/632 | 1/640 |
| PyelonephritisInfections and infestations | 2/632 | 0/640 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 2/632 | 1/640 |
| Rhinovirus infectionInfections and infestations | 2/632 | 1/640 |
| SeizureNervous system disorders | 2/632 | 0/640 |
| Adenovirus infectionInfections and infestations | 0/632 | 2/640 |
| Blood glucose abnormalInvestigations | 1/632 | 0/640 |
| Event | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group |
|---|---|---|
| IrritabilityPsychiatric disorders | 523/632 | 522/640 |
| CoughRespiratory, thoracic and mediastinal disorders | 320/632 | 330/640 |
| Decreased appetiteMetabolism and nutrition disorders | 293/632 | 293/640 |
| VomitingGastrointestinal disorders | 155/632 | 156/640 |
| DiarrhoeaGastrointestinal disorders | 126/632 | 113/640 |
| PyrexiaGeneral disorders | 102/632 | 116/640 |
| Upper respiratory tract infectionInfections and infestations | 63/632 | 69/640 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 28/632 | 40/640 |
| Otitis mediaInfections and infestations | 26/632 | 23/640 |
| Otitis media acuteInfections and infestations | 14/632 | 23/640 |
| Age, Continuous(Weeks) | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group | Total |
|---|---|---|---|
| Mean | 8.7 ± 1.1 | 8.7 ± 1.1 | 8.7 ± 1.1 |
| Sex: Female, Male(Participants) | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group | Total |
|---|---|---|---|
| Female | 308 | 309 | 617 |
| Male | 324 | 331 | 655 |
| Race/Ethnicity, Customized(Participants) | HRV Porcine Circovirus (PCV)-Free Liquid Group | HRV Lyophilized Group | Total |
|---|---|---|---|
| American Indian Or Alaska Native | 8 | 7 | 15 |
| Asian | 20 | 22 | 42 |
| Black Or African American | 74 | 78 | 152 |
| Native Hawaiian Or Other Pacific Islander | 2 | 2 | 4 |
| White | 468 | 471 | 939 |
| Other, not specified | 60 | 60 | 120 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Sep 2017 to primary completion in Oct 2018, 12 months.
Results were first posted in Oct 2019, 1 year after primary completion.
Of 14 phase 3 interventional studies under Rotavirus Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 12 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pediarix · Hiberix · 13-valent pneumococcal vaccine